ABUS vs BMRN · P/E 5.4, rev $6.2M vs P/E 40, rev $2.85B
Arbutus Biopharma Corp (ABUS) versus Biomarin Pharmaceutical Inc (BMRN) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported BMRN revenue for 2024-12-31 was $2.85B. Net income was $426.9M. Revenue was up 18.0% from 2023-12-31 to 2024-12-31. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
Not investment advice. Open the ABUS and BMRN stock pages for the full models.
Not investment advice.